drugset / Trial / NCT04645550
Apixaban, Warfarin and Aspirin Prevents Portal Vein Thrombosis in Patients After Laparoscopic Splenectomy（ESAWAAPT）
RandomizedParallel-groupOpen-labelPrevention
Summary
The purpose of this study is to determine whether Apixaban, Warfarin and Aspirin Anticoagulation are effective and safe in Prevention of Portal Vein Thrombosis in Liver Cirrhotic Patients after Laparoscopic Splenectomy
Timeline
- Start
- 2020-11-22
- Primary completion
- 2023-12-31
- Completion
- 2023-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Apixaban | Small molecule | 2.5 mg | Oral |
| Subject | Aspirin | Small molecule | 100 mg | Oral |
| Subject | Warfarin | Small molecule | 2.5 mg | Oral |
| Background | Dipyridamole | Other / unclassified | 25 mg | Oral |
| Background | Heparin | Other / unclassified | 4100 iu | Subcutaneous |